BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:A booster dose enhances immunogenicity of the COVID-19 vaccine can
 didate ChAdOx1 nCoV-19 in aged mice - Dr Michelle Linterman\, Babraham Ins
 titute
DTSTART:20210224T160000Z
DTEND:20210224T170000Z
UID:TALK154579@talks.cam.ac.uk
CONTACT:Fiona Roby
DESCRIPTION:The spread of SARS-CoV-2 has caused a global pandemic that has
  affected almost every aspect of human life. The development of an effecti
 ve COVID-19 vaccine could limit the morbidity and mortality caused by infe
 ction\, and may enable the relaxation of social distancing measures. Age i
 s one of the most significant risk factors for poor health outcomes after 
 SARS-CoV-2 infection\, therefore it is desirable that any new vaccine cand
 idates elicit a robust immune response in older adults. Here\, we use in-d
 epth immunophenotyping to characterize the innate and adaptive immune resp
 onse induced upon intramuscular administration of the adenoviral vectored 
 ChAdOx1 nCoV-19 (AZD-1222) COVID-19 vaccine candidate in mice. A single va
 ccination generates spike-specific Th1 cells\, Th1-like Foxp3+ regulatory 
 T cells\, polyfunctional spike-specific CD8+ T cells and granzyme B produc
 ing CD8 effectors.  Spike-specific IgG and IgM are generated from both the
  early extrafollicular antibody response and the T follicular helper cell-
 supported germinal centre reaction\, which is associated with the producti
 on of virus neutralising antibodies. A single dose of this vaccine generat
 ed a similar type of immune response in aged mice\, but of a reduced magni
 tude than in younger mice.  We report that a second dose enhances the immu
 ne response to this vaccine in aged mice. This study shows that ChAdOx1 nC
 oV-19 induces both cellular and humoral immunity in adult and aged mice\, 
 and suggests a prime-boost strategy is a rational approach to enhance immu
 nogenicity in older persons. \n\n
LOCATION:Venue to be confirmed
END:VEVENT
END:VCALENDAR